CORT Earnings & Financial Statements
Corcept Therapeutics Incorporated
$113.61
-$2.62(-2.25%)
48
Overall
25
Value
66
Tech
55
Quality
Market Cap
$12.56B
Volume
234.16K
52W Range
$28.66 - $126.38
Target Price
$139.67
CORT earnings and financial statements: Corcept Therapeutics Incorporated's income statement, balance sheet and cash flow statement, annual and quarterly.
CORT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $761.41M | $675.04M | $482.38M | $401.86M | $365.98M |
| Cost of revenue | $12.98M | $10.88M | $6.48M | $5.38M | $5.28M |
| Operating income | $44.80M | $136.95M | $107.28M | $112.63M | $124.48M |
| EBITDA | $68.35M | $162.83M | $126.92M | $119.64M | $127.95M |
| Net income | $99.65M | $141.21M | $106.14M | $101.42M | $112.51M |
| EPS (diluted) | $0.82 | $1.23 | $0.94 | $0.87 | $0.89 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $836.65M | $840.55M | $621.52M | $583.43M | $423.76M |
| Total liabilities | $188.85M | $160.96M | $114.81M | $81.59M | $47.95M |
| Shareholders’ equity | $647.80M | $679.59M | $506.70M | $501.84M | $375.81M |
| Cash and equivalents | $120.50M | $127.67M | $135.55M | $66.33M | $77.62M |
| Long-term debt | $5.02M | $6.11M | - | - | - |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $142.00M | $198.29M | $127.04M | $120.32M | $167.89M |
| Capital expenditure | -$211.0K | -$2.17M | -$139.0K | -$413.0K | -$469.0K |
| Free cash flow | $141.78M | $196.12M | $126.90M | $119.91M | $167.42M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | CORT | $113.61 | -2.3% | 234.16K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Corcept Therapeutics Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW